Axsome Therapeutics has reached a settlement agreement with Hetero Labs Ltd. to resolve patent litigation concerning Axsome's product SUNOSI® (solriamfetol). The legal dispute arose after Hetero submitted an Abbreviated New Drug Application to the U.S. FDA to market a generic version of SUNOSI. According to the settlement terms, Hetero is permitted to sell its generic version starting on or after September 1, 2040, if pediatric exclusivity is granted, or on or after March 1, 2040, if not, contingent upon FDA approval. The agreement will be reviewed by the U.S. Federal Trade Commission and the U.S. Department of Justice. Other similar patent litigations remain ongoing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。